2026-06-14T03:52:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/164852025-05-08T15:31:58Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608

00925njm 22002777a 4500 dc Adlhoch, Cornelia author Delgado-Sanz, Concepcion author Carnahan, AnnaSara author Larrauri, Amparo author Popovici, Odette author Bossuyt, Nathalie author Thomas, Isabelle author Kynčl, Jan author Slezák, Pavel author Brytting, Mia author Guiomar, Raquel author Redlberger-Fritz, Monika author Maistre Melillo, Jackie author Melillo, Tanya author van Gageldonk-Lafeber, Arianne B author Marbus, Sierk D author O'Donnell, Joan author Domegan, Lisa author Gomes Dias, Joana author Olsen, Sonja J author 2023-01 Background: Timely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients. Aim: We assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20. Methods: Case-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained. A mixed effect logistic regression model using country as random intercept was applied to estimate the adjusted odds ratio (aOR) for in-hospital death in patients treated with NAIs vs not treated. Results: Of 19,937 patients, 31% received NAIs within 48 hours of hospital admission. Older age (60-79 years aOR 3.0, 95% CI: 2.4-3.8; 80 years 8.3 (6.6-10.5)) and intensive care unit admission (3.8, 95% CI: 3.4-4.2) increased risk of dying, while early hospital admission after symptom onset decreased risk (aOR 0.91, 95% CI: 0.90-0.93). NAI treatment initiation within 48 hours and up to 7 days reduced risk of dying (0-48 hours aOR 0.51, 95% CI: 0.45-0.59; 3-4 days 0.59 (0.51-0.67); 5-7 days 0.64 (0.56-0.74)), in particular in patients 40 years and older (e.g. treatment within 48 hours: 40-59 years aOR 0.43, 95% CI: 0.28-0.66; 60-79 years 0.50 (0.39-0.63); ≥80 years 0.51 (0.42-0.63)). Conclusion: NAI treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes. Euro Surveill. 2023 Jan;28(4):2200340. 10.2807/1560-7917.ES.2023.28.4.2200340 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 36700868 http://hdl.handle.net/20.500.12105/16485 EU Influenza Antiviral treatment Clinic Epidemiology Fatal outcome Hospital Influenza virus Risk factors Surveillance Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020